SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Bio-Reference Labs (BRLI)

No earlier versions found for this Subject.


Return to Bio-Reference Labs (BRLI)
 
BRLI is the largest independent clinical lab in the New York area
and provides services in 17 states. They recently (9/12) reported
record revenue for 3Q:

1996 1995
Rev(mil) 8.9 8.1
Net/share .06 .05

They also announced acquisition of dialysis testing business from
SmithKline Beecham.

During 1Q ended 1/31/96, company lost .06/share due to harsh winter
weather in NE. If not for severe weather, company believes they would
have shown significant profit based on volume on non-weather affected
days. 2Q & 3Q have demonstrated their continued profitability and
revenue growth.

Current P/E is 16.2. If you consider 1Q loss an anomaly, then P/E
would be under 10.